THERAPY DOSSIER · th-9ce06f4018b3

Human embryonic stem cell derived immunity-and-matrix-regulatory cells (IMRCs)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: IMRC; CAStem
Note: Not recorded

Clinical trials 1

1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT04331613 ↗Injury indicationPHASE1/PHASE2unknown

Safety and efficacy of human embryonic stem cell derived M cells (CAStem) for severe COVID-19 with or without ARDS

COVID-19 · Acute Respiratory Distress Syndrome · Virus; Pneumonia · Acute Lung Injury

Enrolment: 9 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32546764 ↗2020Reported benefit

Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis.

MouseChemical/toxinC57BL/6Intravenous (tail vein in mice, intravenous infusion in monkeys)Biodistribution used 5 x 10^6 DiR-labelled cells in 200 mic…

Model: Bleomycin-induced lung injury and pulmonary fibrosis (1.5 mg/kg bleomycin sulfate intratracheally)

Intravenous IMRCs inhibited pulmonary inflammation and fibrosis and improved survival in a dose-dependent manner, outperforming umbilical cord MSCs and pirfenidone, with an acceptable safety profile in mice and monkeys.

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…